Grading the neuroendocrine tumors of the lung: an evidence-based proposal von Rindi, G, Klersy, C, Inzani, F, Fellegara, G, Ampollini, L, Ardizzoni, A, Campanini, N, Carbognani, P, De Pas, T M, Galetta, D, Granone, P L, Righi, L, Rusca, M, Spaggiari, L, Tiseo, M, Viale, G, Volante, M, Papotti, M, Pelosi, G

Volltext

TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group von Fabbroni, C., Grignani, G., Vincenzi, B., Fumagalli, E., De Pas, T.M., Mazzocca, A., Pantaleo, M.A., Brunello, A., Baldi, G.G., Boglione, A., Fatigoni, S., Berruti, A., Giordano, M., Marrari, A., Dei Tos, A.P., Alberton, A.S., Aliberti, S., Carlucci, L., Rulli, E., Casali, P.G., Sanfilippo, R.

Volltext

Does lung cancer screening with low-dose CT remain promising despite disappointing DANTE results? von Veronesi, Giulia, Maisonneuve, Patrick, De Pas, T M, Bellomi, Massimo

Volltext

Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration von De Pas, T.M., Toffalorio, F., Catania, C., Noberasco, C., Spitaleri, G., Spaggiari, L., De Braud, F.

Volltext

Differentiating neuroblastoma arising in mediastinal germ cell tumour von Pelosi, G, Sonzogni, A, Solli, P, Spaggiari, L, De Pas, T M, Rosai, J

Volltext

The sacral chordoma margin von Radaelli, S., Fossati, P., Stacchiotti, S., Akiyama, T., Asencio, J.M., Bandiera, S., Boglione, A., Boland, P., Bolle, S., Bruland, Ø., Brunello, A., Bruzzi, P., Campanacci, D., Cananzi, F., Capanna, R., Casadei, R., Cordoba, A., Court, C., Dei Tos, A.P., DeLaney, T.F., De Paoli, A., De Pas, T.M., Desai, A., Di Brina, L., Donati, D.M., Fabbri, N., Fiore, M.R., Frezza, A., Gambarotti, M., Gasbarrini, A., Georg, P., Grignani, G., Hindi, N., Hug, E.B., Jones, R., Kawai, A., Krol, A.D., Le Grange, F., Luzzati, A., Marquina, G., Martin-Benlloch, J.A., Mazzocco, K., Navarria, F., Navarria, P., Parchi, P.D., Patel, S., Pennacchioli, E., Petrongari, M.G., Picci, P., Pollock, R., Porcu, L., Quagliuolo, V., Sangalli, C., Scheipl, S., Scotto, G.M., Spalek, M., Steinmeier, T., Timmermann, B., Trama, A., Uhl, M., Valverde, C., Varga, P.P., Verges, R., Weber, D.C., Zoccali, C., Casali, P.G., Sommer, J., Gronchi, A.

Volltext

1690PComparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy von Tarantino, P, Zagami, P, Trillo, P, Conforti, F, Pala, L, Morganti, S, Ferraro, E, Viale, G, Duso, B A, D’Amico, P, Marra, A, Trapani, D, De Pas, T M

Volltext

ACUTE VULVAR VESTIBULITIS OCCURRING DURING CHEMOTHERAPY WITH CRYPTOPHYCIN ANALOGUE LY355703 von De Pas, Tommaso M, Mandalà, Mario, Curigliano, Giuseppe, Peccatori, Fedro

Volltext

Does Lung Cancer Screening with Low-Dose CT Remain Promising Despite Disappointing DANTE Results?/From the Authors von Veronesi, Giulia, Maisonneuve, Patrick, De Pas, T M, Bellomi, Massimo, Infante, Maurizio, Cavuto, Silvio

Volltext

Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of malignant pleural mesothelioma (MPM) von Rea, F., Favaretto, A. G., Marulli, G., Spaggiari, L., De Pas, T. M., Ceribelli, A., Paccagnella, A., Crivellari, G., Russo, F., Ceccarelli, M., Facciolo, F.

Volltext

Increasing awareness of patients with cancer faced with the choice of whether to participate in a phase I clinical trial von Catania, C., De Pas, T. M., Goldhirsch, A., Spitaleri, G., Noberasco, C., Delmonte, A., Radice, D., Adamoli, L., Vecchio, F., De Braud, F. G.

Volltext

PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC) von Sorlini, C., Barni, S., Petrelli, F., Novello, S., De Marinis, F., De Pas, T. M., Grossi, F., Bearz, A., Mencoboni, M., Aieta, M., Caprioli, A., Antonelli, P., Zilembo, N., Bachi, A., Floriani, I., Roder, H., Roder, J., Grigorieva, J., Lazzari, C., Gregorc, V.

Volltext

MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC von Therasse, P., Vansteenkiste, J. F., Zielinski, M., De Pas, T. M., Atanackovic, D., Sequist, L. V., Vallieres, E., Swisher, S., Adams, S., Passlick, B., Eberhardt, W. E. E., Grunenwald, D., Mok, T., Boyer, M., Katz, A., Douillard, J., Debois, M., Brichard, V. G., Altorki, N. K.

Volltext

Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors von Citterio, G., De Braud, F. G., Gregorc, V., De Pas, T. M., Scalamogna, R., Boselli, S., Giovannini, M., Caligaris-Cappio, F., Lambiase, A., Bordignon, C.

Volltext

Initial phase II results with crizotinib in advanced ALK -positive non-small cell lung cancer (NSCLC): PROFILE 1005 von Crinò, L., Kim, D., Riely, G. J., Janne, P. A., Blackhall, F. H., Camidge, D. R., Hirsh, V., Mok, T., Solomon, B. J., Park, K., Gadgeel, S. M., Martins, R., Han, J., De Pas, T. M., Bottomley, A., Polli, A., Petersen, J., Tassell, V. R., Shaw, A. T.

Volltext

Waiting room related symptoms: Patients’ experiences in an outpatient clinic of a cancer center von Catania, C., Micheli, D., Minchella, I., De Pas, T. M., Adamoli, L., Medici, M., Munzone, E., Nolè, F.

Volltext

Expression of gemcitabine and cisplatin-related genes according to histology and stage in non-small-cell lung cancer (NSCLC) von De Pas, T. M., Giovannetti, E., Toffalorio, F., Manzotti, M., Pelosi, G., Spitaleri, G., Minocci, D., Spaggiari, L., Del Tacca, M., de Braud, F. G., Danesi, R.

Volltext

A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors von De Braud, F. G., Gregorc, V., De Pas, T. M., Citterio, G., Scalamogna, R., Boselli, S., Giovannini, M., Caligaris- Cappio, F., Lambiase, A., Bordignon, C.

Volltext

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E von Catania, Chiara, Conforti, Fabio, Spitaleri, Gianluca, Barberis, Massimo, Preda, Lorenzo, Noberasco, Cristina, Lazzari, Chiara, Toffalorio, Francesca, de Marinis, Filippo, Manzotti, Michela, De Pas, Tommaso Martino

Volltext

Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration von De Pas, T. M., Danesi, R., Toffalorio, F., Milani, A., Giovannetti, E., Mey, V., Nannizzi, S., Pelosi, G., Manzotti, M., de Braud, F.

Volltext